The wholesalers that move medicines between drug companies and pharmacies have been fined for failing to call out suspicious transactions involving opioids.
A half-dozen senators involved in confirmation hearings for Rep. Tom Price to head the Department of Health and Human Services have health care investments made by themselves or family members.
Several new studies document widespread conflicts of interest in medicine. The way we think about disease "is being subtly distorted" by financial ties, the authors of an accompanying editorial write.
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives by doing so. But nearly a third of the medicines aren't new or were repurposed many times for financial gain.
Three decades ago, Congress set up a system to encourage drug companies to develop treatments for rare diseases. The law has worked, but at a high cost.
The American Congress of Obstetricians and Gynecologists says pregnant women with morning sickness shouldn't reach hastily for the pill bottle. Controversy over one medicine called Diclegis continues.
The failure of an experimental drug that targets clumps of protein inside the brains of Alzheimer's patients called into question one of the leading theories about the cause of the dementia.
Eight percent of respondents in a recent national poll said they or someone in their household had imported a prescription drug to the U.S. at some point. Are the deals as good as they seem?
Drugmaker Mylan is launching a generic version of its own EpiPen. The lower price could quiet criticism about the high cost of the brand-name anti-allergy drug. There's also a business twist.